IGC Pharma, Inc. (IGC)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $20.42M
Last updated: Nov 17, 2026 at 4:38 PM ET
IGC Pharma, Inc. (IGC) Statistics
IGC Pharma (IGC) has a market cap of $20.42M and an enterprise value of $21.17M. It kept -643.65% of revenue as net income over the last 12 months. Its share count is up 21.04% from a year earlier.
Total Valuation
Enterprise value is 3.68% above the market cap, as debt exceeds cash.
| Market Cap | $20.42M |
|---|---|
| Enterprise Value | $21.17M |
| Latest price (Nov 17, 2026) | $0.19 |
Key Dates
| Last Earnings Date | Nov 6, 2026 |
|---|---|
| Fiscal Year End | March |
Valuation Ratios
| Forward P/S | 20.4x |
|---|---|
| P/B Ratio | 3.0x |
| P/TBV Ratio | 26.0x |
Price Statistics
The stock is down 47.49% over 52 weeks and trades 24.00% below its 50-day average.
| Beta (1Y) | 1.16 |
|---|---|
| 52-Week Change | -47.49% |
| 1-Month Change | -22.31% |
| 3-Month Change | -34.10% |
| 6-Month Change | -33.33% |
| 5-Year Change | -86.79% |
| 10-Year Change | -55.69% |
| Total Return (1Y) | -52.22% |
| Total Return (5Y CAGR) | -32.82% |
| Max Drawdown (1Y) | -52.56% |
| Max Drawdown (3Y) | -73.18% |
| Sharpe Ratio (1Y) | -1.28 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $0.25 |
| 200-Day Average | $0.27 |
| 52-Week Range | $0.17 to $0.36 |
| RSI (14 Days) | 37.1 |
| Average Volume (20 Days) | 460.65K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.39x current liabilities, and total debt is 0.18x shareholder equity.
| Current Ratio | 0.39x |
|---|---|
| Quick Ratio | 0.19x |
| Debt / Equity | 0.18x |
Returns and Efficiency
| Return on Capital Employed (ROCE) | -122.34% |
|---|---|
| ROA (5Y Average) | -79.77% |
| ROIC (5Y Average) | -58.08% |
| Asset Turnover | 0.13x |
Scores
IGC has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue of $1.26M over the last 12 months is up 13.92% from the 12 months before.
| Revenue | $1.26M |
|---|---|
| Revenue Growth (YoY) | +13.92% |
| Gross Profit | $208.00K |
| Operating Income | -$10.11M |
| Pretax Income | -$8.11M |
| Net Income | -$8.11M |
| EBITDA | -$7.87M |
| EBIT | -$8.11M |
| Reported EPS (TTM) | -$0.09 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 66.80% of the $9.73M in total assets.
| Cash and Equivalents | $331.00K |
|---|---|
| Total Debt | $1.08M |
| Net Debt | $751.00K |
| Net Debt Per Share | $0.01 |
| Working Capital | -$1.79M |
| Shareholder Equity | $6.50M |
| Book Value Per Share | $0.06 |
| Tangible Book Value | $761.00K |
| Tangible Book Per Share | $0.01 |
| Total Assets | $9.73M |
| Total Liabilities | $3.23M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$5.21M |
|---|---|
| FCF Per Share | -$0.05 |
| Depreciation and Amortization | $236.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -802.70%.
| Gross Margin | 16.51% |
|---|---|
| Operating Margin | -802.70% |
| Pretax Margin | -643.65% |
| Net Margin | -643.65% |
| EBITDA Margin | -624.92% |
| EBIT Margin | -643.65% |
| Gross Margin (5Y Average) | 46.05% |
Growth
Revenue grew 9.19% a year over 3 years.
| Revenue Growth (3Y CAGR) | +9.19% |
|---|---|
| Revenue Growth (5Y CAGR) | +311.92% |
| Book Value Per Share Growth (2Y CAGR) | -24.93% |
| Tangible Book Per Share Growth (2Y CAGR) | -68.25% |
Stock Splits
The last split was a 1-for-10 reverse split on Apr 19, 2013.
| Last Split Date | Apr 19, 2013 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Analyst Forecast
Consensus estimates put revenue growth at -15.51% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | -15.51% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IGC
What is IGC's market cap?
IGC Pharma has a market cap of $20.42M. Its enterprise value, which adds debt and subtracts cash, is $21.17M.
How many shares of IGC are outstanding?
IGC Pharma has 100.33M shares outstanding. The count is up 21.04% from a year earlier.
Does IGC pay a dividend?
No. IGC Pharma does not pay a dividend.
How much debt does IGC have?
IGC Pharma has $1.08M of total debt and $331.00K of cash and equivalents, a net debt position of $751.00K.
IGC pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors